Trials / Completed
CompletedNCT02160054
Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)
Specified Drug Use-Results Survey of Graceptor® Capsules 0.5mg, 1 mg, and 5 mg in Kidney Transplant Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 289 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of Graceptor ® in patients with kidney transplantation when converted from cyclosporine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Graceptor® | oral |
Timeline
- Start date
- 2013-11-15
- Primary completion
- 2016-03-31
- Completion
- 2016-03-31
- First posted
- 2014-06-10
- Last updated
- 2024-10-21
Locations
30 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02160054. Inclusion in this directory is not an endorsement.